<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nguyen TD</submitter><funding>NIDA NIH HHS</funding><pagination>e221821</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9270692</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3(7)</volume><pubmed_abstract>This cross-sectional study assesses buprenorphine coverage and prior authorization requirements in US commercial formulary data from 2017 to 2021.</pubmed_abstract><journal>JAMA health forum</journal><pubmed_title>Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021.</pubmed_title><pmcid>PMC9270692</pmcid><funding_grant_id>K08 DA048110</funding_grant_id><pubmed_authors>Andraka-Christou B</pubmed_authors><pubmed_authors>Nguyen TD</pubmed_authors><pubmed_authors>Chua KP</pubmed_authors><pubmed_authors>Bradford WD</pubmed_authors><pubmed_authors>Simon K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021.</name><description>This cross-sectional study assesses buprenorphine coverage and prior authorization requirements in US commercial formulary data from 2017 to 2021.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2024-12-04T10:08:46.159Z</modification><creation>2022-08-07T23:45:39.738Z</creation></dates><accession>S-EPMC9270692</accession><cross_references><pubmed>35977219</pubmed><doi>10.1001/jamahealthforum.2022.1821</doi></cross_references></HashMap>